Skip to main content
SpringerLink
Log in

Modulation of P-Glycoprotein-Mediated Multidrug Resistance by Synthetic and Phytochemical Small Molecules, Monoclonal Antibodies, and Therapeutic Nucleic Acids

  • Chapter
  • First Online:
Resistance to Targeted ABC Transporters in Cancer

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT,volume 4))

Abstract

Multidrug resistance of malignant tumors severely hampers their successful treatment frequently leading to fatal consequences for affected patients. During the past three decades, many efforts have been spent to develop strategies to overcome multidrug resistance. Many chemical compounds have been shown to inhibit the drug efflux of the multidrug-resistance-mediating P-glycoprotein. Chemical P-glycoprotein inhibitors are from the classes of calcium channel antagonists, calmodulin inhibitors, cyclosporins, antiarrhythmics, hormones, antimalarials, antibiotics, detergents, beta-blockers, antidepressants, blood pressure lowering indol alkaloids, aerobic glycolysis inhibitors, HIV-protease inhibitors, antimycotics, and others. More recently, chemical compounds from medicinal plants or food were also identified as potent P-glycoprotein inhibitors. P-glycoprotein-inhibiting phytochemicals are from diverse classes, such as flavonoids, nonflavonoid polyphenols, alkaloids, steroids, stilbenes, monoterpenoids, dipterpenoids, triterpenoids, triterpene saponines, lignans, flavolignans, polyketides, carotenoids, and others. In addition to chemical synthetic or natural small molecules several other therapeutic strategies have been devised, e.g. monoclonal antibodies blocking drug efflux, immunotoxins specifically targeting and killing multidrug-resistant cells and therapeutic nucleic acids downregulating the P-glycoprotein encoding the MDR1 gene and resensitizing tumor cells to anticancer drugs. We give an overview of our own research with in vitro and in vivo tumor models in the context of the worldwide efforts to overcome multidrug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ABC:

ATP-binding cassette

ATP:

Adenosine triphosphate Calcein-AM Calcein-acetoxymethylester

CHO Chinese:

hamster ovary

CLO:

Clomipramine

Cpm:

Counts per million DOX Doxorubicin EGC Epigallocatechin EGCG Epigallocatechin-gallate

HIV Human:

immunodeficiency virus

MDR:

Multidrug resistance

MDR1:

Multidrug resistance gene 1

NBD:

Nucleotide binding domain

PBCEC:

Porcine brain capillary endothelial cells

P-gp:

P-glycoprotein

S180:

Sarcoma 180

TAM:

Tamoxifen

TFP:

Trifluperazine

VER:

Verapamil

References

  1. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990;42:155–99.

    CAS  PubMed  Google Scholar 

  2. Volm M, Pommerenke EW. Überwindung der Multidrug-Resistenz bei Tumoren. II. Neue Ansätze. Tumor Diagn Ther. 1992;13:1–5.

    Google Scholar 

  3. Volm M. Multidrug resistance and its reversal. Anticancer Res. 1998;18:2905–17.

    CAS  PubMed  Google Scholar 

  4. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19:1946–2025.

    Article  CAS  PubMed  Google Scholar 

  5. Molnár J, Engi H, Hohmann J, Molnár P, Deli J, Wesolowska O, Michalak K, Wang Q. Reversal of multidrug resistance by natural substances from plants. Curr Top Med Chem. 2010;10:1757–68.

    Article  PubMed  Google Scholar 

  6. Eichhorn T, Efferth T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol. 2012;141:557–70.

    Article  CAS  PubMed  Google Scholar 

  7. Loo TW, Bartlett MC, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J Biol Chem. 2003;278:13603–6.

    Article  CAS  PubMed  Google Scholar 

  8. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem. 1997;250:130–7.

    Article  CAS  PubMed  Google Scholar 

  9. Ferreira RJ, Ferreira MJ, dos Santos DJ. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model. 2013;53:1747–60.

    Article  CAS  PubMed  Google Scholar 

  10. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH. Reversal of multidrug resistance by surfactants. Br J Cancer. 1992;66:62–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323:1718–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Volm M, Brüggemann A, Günther M, Kleine W, Pfleiderer A, Vogt-Schaden M. Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res. 1985;45:5180–5.

    CAS  PubMed  Google Scholar 

  13. Volm M, Drings P, Mattern J, Sonka J, Vogt-Moykopf I, Wayss K. Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer. 1985;56:1396–403.

    Article  CAS  PubMed  Google Scholar 

  14. Pommerenke EW, Osswald H, Hahn EW, Volm M. Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells. Cancer Lett. 1990;55:17–23.

    Article  CAS  PubMed  Google Scholar 

  15. Pommerenke EW, Mattern J, Traugott U, Volm M. Durchbrechung der Multidrug-Resistenz mit (R)-Verapamil in vitro und in vivo. Drug Res. 1991;41:855–8.

    CAS  Google Scholar 

  16. Pommerenke E, Mattern J, Volm M. Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol. 1994;120:422–6.

    Article  CAS  PubMed  Google Scholar 

  17. Pommerenke EW, Volm M. Reversal of doxorubicin-resistance in solid tumors by clomipramine. In Vivo. 1995;9:99–102.

    CAS  PubMed  Google Scholar 

  18. Ozols RF, Cunnion RE, Klecker Jr RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987;5:641–7.

    CAS  PubMed  Google Scholar 

  19. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem. 1999;259:841–50.

    Google Scholar 

  20. Qian XD, Beck WT. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res. 1990;50:1132–7.

    CAS  PubMed  Google Scholar 

  21. Pirker R, Keilhauer G, Raschack M, Lechner C, Ludwig H. Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer. 1990;45:916–9.

    Article  CAS  PubMed  Google Scholar 

  22. Efferth T, Klett T, Mattern J, Osswald H, Pommerenke EW, Stöhr M, Volm M. Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo. Anticancer Res. 1991;11:1275–80.

    CAS  PubMed  Google Scholar 

  23. Klepsch F, Chiba P, Ecker GF. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol. 2011;7:e1002036.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Wöll S, Hee Kim SH, Greten HJ, Efferth T. Animal plant warfare and secondary metabolite evolution. Nat Prod Bioprospect. 2013;3:1–7.

    Article  PubMed Central  Google Scholar 

  25. Stammler G, Volm M. Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines. Anticancer Drugs. 1997;8:265–8.

    Article  CAS  PubMed  Google Scholar 

  26. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis. 2002;28(2):160–8.

    Article  PubMed  Google Scholar 

  27. Adams M, Mahringer A, Bauer R, Fricker G, Efferth T. In vitro cytotoxicity and P-glycoprotein modulating effects of geranylated furocoumarins from Tetradium daniellii. Planta Med. 2007;73:1475–8.

    Article  CAS  PubMed  Google Scholar 

  28. Adams M, Mahringer A, Kunert O, Fricker G, Efferth T, Bauer R. Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med. 2007;73:1554–7.

    Article  CAS  PubMed  Google Scholar 

  29. Mahringer A, Karamustafa S, Klotz D, Kahl S, Konkimalla VB, Wang Y, Wang J, Liu HY, Boechzelt H, Hao X, Bauer R, Fricker G, Efferth T. Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genomics Proteomics. 2010;7:191–205.

    CAS  PubMed  Google Scholar 

  30. Mahringer A, Ardjomand-Woelkart K, Bauer R, Fricker G, Efferth T. Alkamides from Echinacea angustifolia interact with P-glycoprotein of primary brain capillary endothelial cells isolated from porcine brain blood vessels. Planta Med. 2013;79:214–8.

    Article  CAS  PubMed  Google Scholar 

  31. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Efferth T, Lathan B, Volm M. Selective growth-inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4. Br J Cancer. 1991;64:87–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Efferth T, Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol Tumor Pharmacother. 1992;9:11–9.

    CAS  PubMed  Google Scholar 

  34. Kothandan G, Gadhe CG, Madhavan T, Choi CH, Cho SJ. Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain. Eur J Med Chem. 2011;46:4078–88.

    Article  CAS  PubMed  Google Scholar 

  35. Loo TW, Clarke DM. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem. 2001;276:14972–9.

    Article  CAS  PubMed  Google Scholar 

  36. Truant TL, Porcino AJ, Ross BC, Wong ME, Hilario CT. Complementary and alternative medicine (CAM) use in advanced cancer: a systematic review. J Support Oncol. 2013;11:105–13.

    Article  PubMed  Google Scholar 

  37. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78:2131–45.

    Article  CAS  PubMed  Google Scholar 

  38. Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John’s wort drug interactions. Curr Drug Metab. 2008;9:1027–37.

    Article  CAS  PubMed  Google Scholar 

  39. He SM, Yang AK, Li XT, Du YM, Zhou SF. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol. 2010;6:1195–213.

    Article  PubMed  Google Scholar 

  40. Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 2010;17:1635–78.

    Article  CAS  PubMed  Google Scholar 

  41. Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011;12:122–32.

    Article  CAS  PubMed  Google Scholar 

  42. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 2009;12:46–78.

    CAS  PubMed  Google Scholar 

  43. Nabekura T. Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins (Basel). 2010;2:1207–24.

    Article  CAS  Google Scholar 

  44. Wang Z, Ravula R, Cao M, Chow M, Huang Y. Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products. Curr Drug Discov Technol. 2010;7:54–66.

    Article  PubMed  Google Scholar 

  45. Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T, Ono K. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res. 1993;53:5475–82.

    CAS  PubMed  Google Scholar 

  46. Volm M, Efferth T. Overcoming resistance in tumors. Dtsch Med Wochenschr. 1994;119:475–9.

    Article  CAS  PubMed  Google Scholar 

  47. Pommerenke EW, Sinn H, Volm M. Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin. Eur J Cancer. 1995;31A:283–4.

    Article  CAS  PubMed  Google Scholar 

  48. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Volm M, Mattern J, Efferth T. P-Glykoprotein als Marker für Multidrug-Resistenz in Tumoren und Normalgewebe. Tumor Diagn Ther. 1990;11:189–97.

    Google Scholar 

  50. Volm M, Pommerenke EW, Efferth T, Löhrke H, Mattern J. Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro. Cancer. 1991;67:2484–9.

    Article  CAS  PubMed  Google Scholar 

  51. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem. 2011;50:209–32.

    Article  CAS  PubMed  Google Scholar 

  52. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat. 2012;15:50–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Kuete V, Sandjo LP, Ouete JL, Fouotsa H, Wiench B, Efferth T. Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines. Phytomedicine. 2013;pii: S0944-7113(13)00321-8.

    Google Scholar 

  54. Kuete V, Sandjo LP, Kwamou GM, Wiench B, Nkengfack AE, Efferth T. Activity of three cytotoxic isoflavonoids from Erythrina excelsa and Erythrina senegalensis (neobavaisoflavone, sigmoidin H and isoneorautenol) toward multi-factorial drug resistant cancer cells. Phytomedicine. 2013;pii: S0944-7113(13)00426-1.

    Google Scholar 

  55. Volm M, Efferth T, Günther A, Lathan B. Detection of murine S180 cells expressing a multidrug resistance phenotype using different in vitro test systems and a monoclonal antibody. Drug Res. 1987;37:862–7.

    CAS  Google Scholar 

  56. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012;15:98–105.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Saeed M, Greten J, Efferth T. Collateral sensitivity in drug-resistant tumor cells. In: Bonavida B, editor. Tumor cell resistance to apoptosis by cytotoxic drugs and reversal of resistance by targeted sensitizing cells. New York: Springer; 2013. p. 187–211.

    Google Scholar 

  58. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61–9.

    Article  CAS  PubMed  Google Scholar 

  59. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.

    Article  CAS  PubMed  Google Scholar 

  60. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21:39–49.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Curiel TJ. Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resist Updat. 2012;15:106–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD, ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112:326–30.

    Article  CAS  PubMed  Google Scholar 

  63. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS, MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12:642–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32:92.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Efferth T, Volm M. Modulation of P-glycoprotein mediated multidrug-resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology. 1993;50:303–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany

    Thomas Efferth & Maen Zeino

  2. Kleegarten 9, 69123, Heidelberg, Germany

    Manfred Volm

Authors
  1. Thomas Efferth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maen Zeino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Volm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Efferth .

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany

    Thomas Efferth

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Efferth, T., Zeino, M., Volm, M. (2015). Modulation of P-Glycoprotein-Mediated Multidrug Resistance by Synthetic and Phytochemical Small Molecules, Monoclonal Antibodies, and Therapeutic Nucleic Acids. In: Efferth, T. (eds) Resistance to Targeted ABC Transporters in Cancer. Resistance to Targeted Anti-Cancer Therapeutics, vol 4. Springer, Cham. https://doi.org/10.1007/978-3-319-09801-2_7

Download citation

Publish with us

Policies and ethics

Search

Navigation